Role of Aprotinin in Glucagon Degradation, Measurement by Radioimmunoactive Method (RIA) I125

University Hospital, Gentofte, Copenhagen

Status: Completed

Conditions: Hyperglucagonemia

Treatments: Other: Fasting glycemia; Other: Hypoglycemia

Study type: Interventional

Funder types: Other

Identifiers

NCT01436734

H-D-2009-0078

Details and patient eligibility

About

The aim of the study was to investigate the role of the Trasylol in glucagon prevention in degradation using radioimmunoactive method with I125. Additionally different incubation time was introduced in human plasma samples after oral glucose stimulation, also in fasted and hypoglycemia blood samples from patients' type 2 diabetes. Since, the structure and the techniques for the glucagon measurement are well described nowadays.

Enrollment: 5 patients

Sex: Male

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Caucasians 18 years or older with Type 2 diabetes (WHO criteria)

Exclusion criteria

• HbA1c >9 %
• Liver disease (ALAT/ASAT >2 x upper normal limit)
• Diabetic nephropathy (s-creatinine >130 µM or albuminuria)
• Proliferative diabetic retinopathy (anamnestic)
• Severe arteriosclerosis or heart failure (NYHA group III og IV)
• Anemia
• treatment with medication not applicable to pause for 12 hours
• pregnancy or lactation
• Fasting plasma glucose >15 mM on screening day.

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

5 participants in 1 patient group

GIP

Experimental group

Treatment:

Other: Hypoglycemia

Other: Fasting glycemia